Viskart-p Suspension

Visko Pharmacy Limited
9/26 Udi Road Asata, Enugu, Enugu State, Nigeria.
Tel: 234-80-35085021, 234-70-31601265, 234-80-37430071

Brand Name

Viskart-p Suspension


Shandong Xier Kangtai Pharmaceutical Co., Ltd

Private Economy Garden, Xinyan Town, YANZHOU City, Shondong China.

Therapeutic Class

Antimalarial drugs

Dosage Form, Composition & NAFDAC Registration Number (NRN)

Suspension (NRN: B4-3248): Dihydroartemisinin 80 mg/100 mL; Piperaquine Phosphate 640 mg/100 mL;

Pack size: 1 x 10's.


Dihdroaetemisin mainly interferes with the membrane structure of trophozoites (erythrocytic asexual forms).i.e. whorled food vacuole membrane, distended mitochondria, swollen nuclear membranes, dissociation of ribosomes from endoplasmic reticulum leading to cytoplasmic vacuolization and autophagocytosis. In addition, bichemical depression of protein synthesis and nucleic acid synthesis are exhibited.

Upon oral admini Dihydroartemisinin is rapidly absorbed and maximum blood concentration attained 1 hour afterwards,with a half-life of about 4 hours. It is widely distributed in the liver, kidney and bile. Approximately 80% is excreted through the urine and faeces within 24 hrs after administration. It is metabolized to two inactive metabolites, deoxydihydroartemisinin and dihydroxydihydroartemisin.


Treatment of clinical attacks of malarial caused by P.vivax and P.malariae.



The product is not recommended for use in woman during the first 3 months of pregnancy


Do not exceed the stated dosage

Lactation: excretion of VISKART-P ORAL SUSPENSION through breast milk has not established.


Avoid concomitant administration with drugs that may increase the QT interval.

Adverse Effects

Nausea or vomiting may occur occasionally with incidence of less than 6%.

No notice side effect of Dihdroartemisinin in reported.

The Dihydroartemisinin would, for certain individuals,bring effects of greater or lesser severity: for example, a reversible reduction in reticulocyte counts.

Possible side-effect of PQP includes mild dizziness, vertigo, headache, nausea,vomiting and abdominal discomfort. Reversible leucopenia was infrequently reported. Dyspnea and palpitations were also reported but not further specified.

Dosage & Administration

Oral administration: Patient should follow doctor's instruction. The recommended dosages are in the following table. 

Body weight in kgs

                   Number of Mililiters





5 kg

10.5 mL

10.5 mL

10.5 mL

7.5 kgs

16 mL

16 mL

16 mL

10.0 kgs

21 mL

21 mL

21 mL

12.5 kg

26 mL

26 mL

26 mL

15.0 kg

31.5 mL

31.5 mL

31.5 mL

Above dosages are based on formula. i.e. Volume required per day in mL = 2.1 x bodyweight.

Storage/Handling Recommendations

VISKAR-P SUSPENSION should be stored in a cool at dry place, below 25oC, protect from light.

Keep out of reach of children.

Review Date

2016-10-28 04:53:10